US Generics Market Continues To Seek Stability
Firms Adopt Varying Strategies To Ride Out Ongoing Turbulence In The US
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
You may also be interested in...
Mayne’s 2022 results take stock of pivotal changes, with the Australian firm drawing down its generics portfolio as it focuses on the US branded products market. These new priorities come amid a high-value asset sale and a change in CEO.
Overcoming residual negative perceptions around generics, reforming Medicaid and Medicare policies that unfairly penalize generics and ensuring that “skinny label” generics can continue to be marketed are among the key priorities for Sandoz in the US, Carol Lynch, president of Sandoz Inc. and head of North America, tells Generics Bulletin in an exclusive interview.
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.